Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 5 versus ADHANSIA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 5 versus ADHANSIA XR.
ADDERALL 5 vs ADHANSIA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
None Documented
None Documented
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary pH >7.
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant